[go: up one dir, main page]

NO990948D0 - Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av HTLV-1-infeksjoner - Google Patents

Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av HTLV-1-infeksjoner

Info

Publication number
NO990948D0
NO990948D0 NO990948A NO990948A NO990948D0 NO 990948 D0 NO990948 D0 NO 990948D0 NO 990948 A NO990948 A NO 990948A NO 990948 A NO990948 A NO 990948A NO 990948 D0 NO990948 D0 NO 990948D0
Authority
NO
Norway
Prior art keywords
htlv
medication
infections
preparation
treatment
Prior art date
Application number
NO990948A
Other languages
English (en)
Other versions
NO990948L (no
Inventor
Michael R Jirousek
Douglas K Ways
Lawrence E Stramm
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO990948D0 publication Critical patent/NO990948D0/no
Publication of NO990948L publication Critical patent/NO990948L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO990948A 1996-08-30 1999-02-26 Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av HTLV-1-infeksjoner NO990948L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2493896P 1996-08-30 1996-08-30
US08/917,517 US5962446A (en) 1996-08-30 1997-08-26 Therapetutic treatment for human T cell lymphotrophic virus type 1 infection
PCT/US1997/015524 WO1998008508A1 (en) 1996-08-30 1997-08-28 Use of pkc inhibitors for the manufacture of a medicament for the treatment of htlv-1 infections

Publications (2)

Publication Number Publication Date
NO990948D0 true NO990948D0 (no) 1999-02-26
NO990948L NO990948L (no) 1999-04-28

Family

ID=26699066

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990948A NO990948L (no) 1996-08-30 1999-02-26 Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av HTLV-1-infeksjoner

Country Status (14)

Country Link
US (1) US5962446A (no)
EP (1) EP0830861A1 (no)
JP (1) JP2002514176A (no)
KR (1) KR20000035864A (no)
CN (1) CN1231608A (no)
AU (1) AU4179397A (no)
BR (1) BR9711366A (no)
CA (1) CA2263161A1 (no)
EA (1) EA199900243A1 (no)
IL (1) IL128493A0 (no)
NO (1) NO990948L (no)
PL (1) PL331759A1 (no)
TR (1) TR199900905T2 (no)
WO (1) WO1998008508A1 (no)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US5063238A (en) * 1989-11-13 1991-11-05 Merrell Dow Pharmaceuticals Inc. Prevention of glycoprotein enveloped virus infectivity by pyridinyloxazole-2-ones
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
DK0657411T3 (da) * 1993-12-07 1999-11-15 Lilly Co Eli Forbedret syntese af bisindolylmaleimider
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
UA44690C2 (uk) * 1993-12-07 2002-03-15 Елі Ліллі Енд Компані Макроциклічна сполука іміду біс-індол-малеїнової кислоти, спосіб її одержання та фармацевтична композиція, макроциклічні сполуки іміду біс-індол-малеїнової кислоти та біс-індол-малеїнового ангідриду, спосіб одержання (варіанти)
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
NO990948L (no) 1999-04-28
WO1998008508A1 (en) 1998-03-05
JP2002514176A (ja) 2002-05-14
TR199900905T2 (xx) 1999-07-21
IL128493A0 (en) 2000-01-31
EP0830861A1 (en) 1998-03-25
EA199900243A1 (ru) 1999-10-28
KR20000035864A (ko) 2000-06-26
CN1231608A (zh) 1999-10-13
PL331759A1 (en) 1999-08-02
AU4179397A (en) 1998-03-19
US5962446A (en) 1999-10-05
BR9711366A (pt) 1999-08-17
CA2263161A1 (en) 1998-03-05

Similar Documents

Publication Publication Date Title
DE69525148D1 (de) Pharmazeutische formulierung
NO981008L (no) Farmas÷ytisk formulering
CY2007001I2 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
CY2006007I2 (el) Χρηση αναστολεων cgmp-φωσφοδιεστερασης στην αγωγη της ανικανοτητας
FI955782L (fi) Menetelmä kivun käsittelemiseksi 24-tunnin suun kautta annettavia opioidiformulointeja, joilla saadaan lääkkeen plasmatason nopea alkunousu
EE200000770A (et) Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks
EE9700241A (et) Farmatseutiline kompositsioon transdermaalseks manustamiseks
DK0984773T3 (da) Farmaceutisk formulering med omeprazol
FI971279A0 (fi) Lääkkeitä
EE9800042A (et) Inhalaatorites kasutatav seade
NO954486D0 (no) Farmasöytiske formuleringsgrunnlag
NO20016198L (no) Orale farmasöytiske sammensetninger som inneholder taxaner og fremgangsmåter for anvendelse av samme i behandling
NO20005179D0 (no) Medikament behandling
DK0871438T3 (da) Anvendelse af alfa-hydroxysyrer ved fremstillingen af et medikament til behandling af inflammation
NO984759D0 (no) Anvendelse av en osmolytt ved fremstilling av et medikament for behandling av komplikasjoner forÕrsaket av iskemi
PT932400E (pt) Derivados de anticonvulsionantes uteis no tratamento da dor neuropatica
EP0617956A3 (en) Piroxicam containing analgesic anti-inflammatory patch.
NO990949D0 (no) Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av AIDS
DK0866699T3 (da) Anvendelse af cholinesteraseinhibitorer til fremstilling af et medikament til behandling af xerostomi
NO990948D0 (no) Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av HTLV-1-infeksjoner
FI964918L (fi) Lääkeainesuoloja
DE19681529D2 (de) Pharmazeutische Darreichungsform
LV11966A (lv) Pretiekaisumu lidzeklis arigai lietosanai
KR950032276U (ko) 의약품 투여용 피부 흠집 형성구
NO996117D0 (no) Anordning for tilfoering av medikamenter samt behandling av virale og mikrobielle infeksjoner og taer ingssyndrom

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application